Related Experiment Video
Updated: Sep 17, 2025

Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence
Published on: February 10, 2023
Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer
Shouhai Zhu1, Huanyao Gao2, Dan Jiang2
1Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with deleterious BRCA1/2 alterations. Although this marks a significant milestone, intrinsic or acquired therapy resistance remains a major challenge that limits clinical efficacy. Here, we demonstrate that dysregulated ubiquitination and turnover by the cullin 3 (CUL3)ZBTB2 E3 ligase complex induce the upregulation of the short isoform of nuclear-receptor-binding SET domain protein 3 (NSD3) (NSD3S), which confers PARPi resistance in prostate cancer cells and patient-derived mCRPC samples. Mechanistically, ATR drives the localization of NSD3S at stalled replication forks, where it antagonizes the PTIP-dependent recruitment of the MRE11 nuclease, thereby protecting nascent DNA from extensive degradation and ensuring fork stabilization. Importantly, pharmacological degradation of NSD3S using an NSD3-targeting proteolysis-targeting chimera (PROTAC) efficiently enhances PARPi sensitivity in both cell-line-derived xenograft and patient-derived xenograft (PDX) mouse models. These findings establish NSD3S as a key determinant of PARPi toxicity in mCRPC.
Insights
Short isoform of nuclear-receptor-binding SET domain protein 3 (NSD3S) drives resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) in prostate cancer. Targeting NSD3S with PROTACs restores PARPi sensitivity, offering a new therapeutic strategy for mCRPC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Poly (ADP-ribose) polymerase inhibitors (PARPi) show efficacy in metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 alterations.
- Therapy resistance to PARPi remains a significant clinical challenge, limiting treatment effectiveness.
Purpose of the Study:
- To investigate the mechanisms underlying PARPi resistance in mCRPC.
- To identify novel therapeutic targets for overcoming PARPi resistance.
Main Methods:
- Investigated the role of cullin 3 (CUL3)ZBTB2 E3 ligase complex in regulating NSD3.
- Utilized cell-line-derived xenograft and patient-derived xenograft (PDX) mouse models.
- Employed NSD3-targeting proteolysis-targeting chimera (PROTAC) to degrade NSD3S.
Main Results:
- Dysregulated ubiquitination by CUL3ZBTB2 upregulates NSD3S, conferring PARPi resistance.
- NSD3S localizes at stalled replication forks, antagonizing MRE11 recruitment and stabilizing DNA.
- Pharmacological degradation of NSD3S using PROTACs enhances PARPi sensitivity in preclinical models.
Conclusions:
- NSD3S is a key driver of PARPi resistance in mCRPC.
- Targeting NSD3S degradation represents a promising strategy to improve PARPi efficacy in prostate cancer.
More Related Videos
Related Concept Videos
Single-Strand DNA Binding Proteins
DNA Damage can Stall the Cell Cycle
Restarting Stalled Replication Forks
The DNA Replication Fork
Long-patch Base Excision Repair
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...

